Between 2017 and 2019, he also served as Director of the CSIR-Institute of Microbial Technology, one of India’s premier biomedical laboratories. Anil is a member of the Board of Directors at Janssen Pharmaceutica NV, Belgium, and Scientific Advisory Board member for Council of Scientific and Industrial Research (CSIR), Government of India. He is also a core member of the United Nations Stop TB Partnership Group on the discovery of new drugs.

Anil received his Ph.D. from the Max Planck Institute for Biochemistry, Germany and IGIB, Delhi University and has more than 20 years of experience in drug discovery. Anil has played a key role in discovery and development of Bedaquiline - the first drug to be approved in last 45 years for treatment of drug-resistant tuberculosis. Bedaquiline has been conditionally approved in over 64 countries and has reached more than 300,000 TB patients across the world and is on WHO’s list of ‘essential medicines. He has also discovered novel drugs against several respiratory viral pathogens, some of which are currently in late-stage clinical trials.

For the discovery of Bedaquiline and TB research, Anil received several awards. In 2020, he was awarded the American Chemical Society’s annual “Heroes of Chemistry” award and in 2017, he was awarded the ‘Sun Pharma Research Award’ and “Swiss TB Prize” by society of pneumology, Switzerland. Anil was also a member of the Janssen team that was awarded 2016’s “Prix Galien French prize” for the discovery of Bedaquiline. He has published in leading scientific journals such as Nature and Science and holds more than 25 international patents.